NKGen Biotech publishes phase 1 troculeucel trial results for Alzheimer's treatment
- Phase 1 trial of troculeucel showed stable/improved outcomes in 90% of subjects with no drug-related adverse events.
- The therapy was well-tolerated and reduced neuroinflammatory biomarkers, with dose-dependent decreases in pTau181 and GFAP.
- A larger trial with higher dosing is ongoing in the U.S.
- Follow-up Phase 1/2a trial is enrolling patients for the Phase 2 cohort.
Read more
Encoded Therapeutics reports clinical progress of ETX101 gene therapy for Dravet syndrome
- ETX101 is an AAV9-based gene therapy targeting SCN1A+ Dravet syndrome, with ongoing trials in the US, UK, and Australia.
- Eight patients have been treated with multiple dose levels, showing no treatment-related serious adverse events.
- Preliminary safety and efficacy data are expected in the second half of 2025.
- ETX101 has received Fast Track, Rare Pediatric, and Orphan Drug Designations from the FDA and Orphan Designation from the EMA.
Read more
NeuroPace announces pricing of public offering of $65 million of common stock
- NeuroPace has priced an underwritten public offering of 6,500,000 shares at $10.00 per share.
- The offering is expected to generate gross proceeds of $65 million, with a closing date of February 18, 2025.
- A 30-day option allows underwriters to purchase an additional 975,000 shares at the same price.
- Proceeds will be used for share repurchase, clinical trials, R&D, and general corporate purposes.
Read more
